S5-7.2 – Identifying the target MASH patients for Rezdiffra
Leading patient advocates help the Surfers identify the target MASH patients for Rezdiffra and discuss Madrigal’s extensive patient support program.
March 22, 2024
Leading patient advocates help the Surfers identify the target MASH patients for Rezdiffra and discuss Madrigal’s extensive patient support program.
Last Thursday, March 14, Rezdiffra (resmetirom) became the first drug approved in the US for MASH. Five leading North American MASLD patient advocates join the Surfers to discuss their feelings about this approval along with the opportunities and challenges that lie ahead.
The conversation on Rezdiffra, the first MASH drug, wraps up with the panelists answering a inviation to discuss any other issues of interest that had not arisen in the conversation.
This conversation focuses on what panelists believe to be the major lessons the BioPharma industry should take from Madrigal’s success in bring Rezdiffra to launch.
The launch of Rezdiffra raises this pivotal question: which MASH patients are the correct initial targets for the first MASH drug?
SurfingMASH’s coverage of the Rezdiffra approval shifts to a seemingly tangential topic: impact of drug approval on patient adherence with lifestyle recommendations.
Last Thursday, FDA approved Rezdiffra, the first MASH drug! A global panel of key opinion leaders joins the Surfers to share excitement and discuss the implications of this landmark event.
This final conversation focuses on semaglutide and some of the dual- and triple-increting agonists and then reviews high points of the entire episode.
This conversation includes two separate themes: the rationale and impact around the price of resmetirom, and the impact of GLP-1s on resmetirom use in patients with MASH.
This conversation looks at different strategies to improve NITs in the diagnosis and staging of patients with advanced MASH Fibrosis.